TY - JOUR
T1 - Visual Evoked Potentials as a Biomarker in Multiple Sclerosis and Associated Optic Neuritis
AU - Leocani, L
AU - Guerrieri, Simone
AU - Comi, G
PY - 2018
Y1 - 2018
N2 - Multiple sclerosis (MS) is an inflammatory, degenerative disease of the central nervous system (CNS) characterized by progressive neurological decline over time. The need for better "biomarkers" to more precisely capture and track the effects of demyelination, remyelination, and associated neuroaxonal injury is a well-recognized challenge in the field of MS. To this end, visual evoked potentials (VEPs) have a role in assessing the extent of demyelination along the optic nerve, as a functionally eloquent CNS region. Moreover, VEPs testing can be used to predict the extent of recovery after optic neuritis (ON) and capture disabling effects of clinical and subclinical demyelination events in the afferent visual pathway. In this review, the evolving role of VEPs in the diagnosis of patients with ON and MS and the utility of VEPs testing in determining therapeutic benefits of emerging MS treatments is discussed. © 2018 by North American Neuro-Ophthalmology Society.
AB - Multiple sclerosis (MS) is an inflammatory, degenerative disease of the central nervous system (CNS) characterized by progressive neurological decline over time. The need for better "biomarkers" to more precisely capture and track the effects of demyelination, remyelination, and associated neuroaxonal injury is a well-recognized challenge in the field of MS. To this end, visual evoked potentials (VEPs) have a role in assessing the extent of demyelination along the optic nerve, as a functionally eloquent CNS region. Moreover, VEPs testing can be used to predict the extent of recovery after optic neuritis (ON) and capture disabling effects of clinical and subclinical demyelination events in the afferent visual pathway. In this review, the evolving role of VEPs in the diagnosis of patients with ON and MS and the utility of VEPs testing in determining therapeutic benefits of emerging MS treatments is discussed. © 2018 by North American Neuro-Ophthalmology Society.
U2 - 10.1097/WNO.0000000000000704
DO - 10.1097/WNO.0000000000000704
M3 - Article
VL - 38
SP - 350
EP - 357
JO - Journal of Neuro-Ophthalmology
JF - Journal of Neuro-Ophthalmology
SN - 1070-8022
IS - 3
ER -